Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free AZRX Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

AzurRx BioPharma (AZRX) Competitors

AzurRx BioPharma logo
Compare

AZRX vs. PYRGF, IBIO, HYFT, NBRV, and LITS

Should you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include PyroGenesis Canada (PYRGF), iBio (IBIO), MindWalk (HYFT), Nabriva Therapeutics (NBRV), and Lite Strategy (LITS).

How does AzurRx BioPharma compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

PyroGenesis Canada has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.

In the previous week, PyroGenesis Canada had 1 more articles in the media than AzurRx BioPharma. MarketBeat recorded 1 mentions for PyroGenesis Canada and 0 mentions for AzurRx BioPharma. PyroGenesis Canada's average media sentiment score of 0.00 equaled AzurRx BioPharma'saverage media sentiment score.

Company Overall Sentiment
PyroGenesis Canada Neutral
AzurRx BioPharma Neutral

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by company insiders. Comparatively, 7.3% of AzurRx BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

AzurRx BioPharma has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat AzurRx BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
PyroGenesis Canada-115.14% N/A -60.81%
AzurRx BioPharma N/A -482.96%-258.47%

PyroGenesis Canada has higher revenue and earnings than AzurRx BioPharma. PyroGenesis Canada is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PyroGenesis Canada$9.14M7.31-$21.12M-$0.05N/A
AzurRx BioPharmaN/AN/A-$32.67M-$11.50N/A

Summary

PyroGenesis Canada beats AzurRx BioPharma on 7 of the 11 factors compared between the two stocks.

How does AzurRx BioPharma compare to iBio?

iBio (NASDAQ:IBIO) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

iBio presently has a consensus target price of $4.75, indicating a potential upside of 177.78%. Given iBio's stronger consensus rating and higher probable upside, equities research analysts plainly believe iBio is more favorable than AzurRx BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iBio
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
3 Strong Buy rating(s)
3.17
AzurRx BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

iBio has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.

iBio has higher revenue and earnings than AzurRx BioPharma. iBio is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iBio$400K154.50-$18.38M-$1.00N/A
AzurRx BioPharmaN/AN/A-$32.67M-$11.50N/A

iBio's return on equity of -71.26% beat AzurRx BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
iBioN/A -71.26% -57.92%
AzurRx BioPharma N/A -482.96%-258.47%

7.9% of iBio shares are owned by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Comparatively, 7.3% of AzurRx BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, iBio had 2 more articles in the media than AzurRx BioPharma. MarketBeat recorded 2 mentions for iBio and 0 mentions for AzurRx BioPharma. iBio's average media sentiment score of 1.66 beat AzurRx BioPharma's score of 0.00 indicating that iBio is being referred to more favorably in the media.

Company Overall Sentiment
iBio Very Positive
AzurRx BioPharma Neutral

Summary

iBio beats AzurRx BioPharma on 12 of the 15 factors compared between the two stocks.

How does AzurRx BioPharma compare to MindWalk?

AzurRx BioPharma (NASDAQ:AZRX) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

In the previous week, AzurRx BioPharma's average media sentiment score of 0.00 equaled MindWalk'saverage media sentiment score.

Company Overall Sentiment
AzurRx BioPharma Neutral
MindWalk Neutral

6.3% of AzurRx BioPharma shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 7.3% of AzurRx BioPharma shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AzurRx BioPharma has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

MindWalk has a consensus target price of $5.00, indicating a potential upside of 293.70%. Given MindWalk's stronger consensus rating and higher probable upside, analysts plainly believe MindWalk is more favorable than AzurRx BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AzurRx BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
MindWalk
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

MindWalk has higher revenue and earnings than AzurRx BioPharma. MindWalk is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AzurRx BioPharmaN/AN/A-$32.67M-$11.50N/A
MindWalk$28.08M2.09-$21.69M-$0.20N/A

AzurRx BioPharma has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. MindWalk's return on equity of -69.37% beat AzurRx BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
AzurRx BioPharmaN/A -482.96% -258.47%
MindWalk -66.79%-69.37%-39.74%

Summary

MindWalk beats AzurRx BioPharma on 10 of the 14 factors compared between the two stocks.

How does AzurRx BioPharma compare to Nabriva Therapeutics?

AzurRx BioPharma (NASDAQ:AZRX) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

AzurRx BioPharma has higher earnings, but lower revenue than Nabriva Therapeutics. AzurRx BioPharma is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AzurRx BioPharmaN/AN/A-$32.67M-$11.50N/A
Nabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A

AzurRx BioPharma has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.

6.3% of AzurRx BioPharma shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 7.3% of AzurRx BioPharma shares are held by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

AzurRx BioPharma has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Nabriva Therapeutics' return on equity of -365.53% beat AzurRx BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
AzurRx BioPharmaN/A -482.96% -258.47%
Nabriva Therapeutics -148.11%-365.53%-135.81%

In the previous week, Nabriva Therapeutics had 1 more articles in the media than AzurRx BioPharma. MarketBeat recorded 1 mentions for Nabriva Therapeutics and 0 mentions for AzurRx BioPharma. AzurRx BioPharma's average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.

Company Overall Sentiment
AzurRx BioPharma Neutral
Nabriva Therapeutics Neutral

Summary

Nabriva Therapeutics beats AzurRx BioPharma on 6 of the 11 factors compared between the two stocks.

How does AzurRx BioPharma compare to Lite Strategy?

Lite Strategy (NASDAQ:LITS) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Lite Strategy has higher revenue and earnings than AzurRx BioPharma. Lite Strategy is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lite Strategy$65.30M0.68-$15.94M-$1.33N/A
AzurRx BioPharmaN/AN/A-$32.67M-$11.50N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lite Strategy
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
AzurRx BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Lite Strategy has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.

52.4% of Lite Strategy shares are owned by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are owned by institutional investors. 1.6% of Lite Strategy shares are owned by insiders. Comparatively, 7.3% of AzurRx BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lite Strategy's return on equity of -68.86% beat AzurRx BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Lite StrategyN/A -68.86% -67.48%
AzurRx BioPharma N/A -482.96%-258.47%

In the previous week, Lite Strategy's average media sentiment score of 0.00 equaled AzurRx BioPharma'saverage media sentiment score.

Company Overall Sentiment
Lite Strategy Neutral
AzurRx BioPharma Neutral

Summary

Lite Strategy beats AzurRx BioPharma on 7 of the 10 factors compared between the two stocks.

Get AzurRx BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZRX vs. The Competition

Export
MetricAzurRx BioPharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$19.40M$904.51M$6.25B$12.13B
Dividend YieldN/A4.84%2.78%5.20%
P/E Ratio-0.191.5620.8825.39
Price / SalesN/A121.19533.4678.15
Price / CashN/A20.0743.2953.47
Price / Book-2.747.719.986.81
Net Income-$32.67M-$5.06M$3.54B$332.87M

AzurRx BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZRX
AzurRx BioPharma
N/A$2.08
-3.7%		N/A+485.3%$19.40MN/AN/A12
PYRGF
PyroGenesis Canada
N/A$0.29
+4.9%		N/A-8.7%$60.12M$9.14MN/A90
IBIO
iBio
4.3008 of 5 stars		$1.60
-5.6%		$4.75
+197.8%		N/A$57.64M$400KN/A100
HYFT
MindWalk
2.147 of 5 stars		$1.19
-0.4%		$5.00
+321.9%		N/A$54.70M$17.59MN/A80
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59MN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AZRX) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Nobody's Asking Where The SpaceX Money Comes From
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel